Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Pardes Biosciences Inc (PRDS)

Pardes Biosciences Inc (PRDS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 133,946
  • Shares Outstanding, K 62,012
  • Annual Sales, $ 0 K
  • Annual Income, $ -96,630 K
  • 60-Month Beta 0.42
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.86
Trade PRDS with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.29
  • Most Recent Earnings $-0.18 on 08/04/23
  • Latest Earnings Date 08/21/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate -0.27
  • Number of Estimates 1
  • High Estimate -0.27
  • Low Estimate -0.27
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +32.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.06 +4.85%
on 08/10/23
2.19 -1.59%
on 08/30/23
+0.06 (+2.86%)
since 07/28/23
3-Month
1.77 +22.03%
on 07/05/23
2.19 -1.59%
on 08/30/23
+0.27 (+14.29%)
since 05/30/23
52-Week
0.75 +188.00%
on 11/29/22
3.93 -45.04%
on 08/29/22
-1.54 (-41.62%)
since 08/26/22

Most Recent Stories

More News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DEN, PRDS, HCCI

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

DEN : 88.66 (-0.26%)
PRDS : 2.16 (unch)
HCCI : 45.51 (+0.09%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRDS, CCF, NLTX, SCU

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

PRDS : 2.16 (unch)
CCF : 127.49 (+0.04%)
NLTX : 13.96 (+1.45%)
SCU : 12.72 (-0.24%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, DEN, PRDS, FREQ

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

AEL : 56.31 (+0.18%)
DEN : 88.66 (-0.26%)
PRDS : 2.16 (unch)
FREQ : 14.9800 (+5.94%)
Moore Kuehn Encourages PRDS, AMNB, NLTX, and SCU Investors to Contact Law Firm

/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...

PRDS : 2.16 (unch)
AMNB : 47.76 (-0.33%)
NLTX : 13.96 (+1.45%)
SCU : 12.72 (-0.24%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEWR, AEL, PRDS

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

NEWR : 86.99 (+0.02%)
AEL : 56.31 (+0.18%)
PRDS : 2.16 (unch)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCU, PRDS, NLTX, AJX

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

SCU : 12.72 (-0.24%)
PRDS : 2.16 (unch)
NLTX : 13.96 (+1.45%)
AJX : 3.49 (+1.45%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRDS, KDNY, AEL

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

PRDS : 2.16 (unch)
KDNY : 40.39 (+0.22%)
AEL : 56.31 (+0.18%)
Shareholder Alert: Ademi LLP investigates whether Pardes Biosciences, Inc. has obtained a Fair Price in its transaction with MediPacific

/PRNewswire/ -- Ademi LLP is investigating Pardes (Nasdaq: PRDS) for possible breaches of fiduciary duty and other violations of law in its transaction with...

PRDS : 2.16 (unch)
RM LAW Announces Investigation of Pardes Biosciences, Inc.

/PRNewswire/ -- RM LAW, P.C. is investigating potential claims against the board of directors of Pardes Biosciences, Inc. ("Pardes" or the "Company") (NASDAQ:...

PRDS : 2.16 (unch)
Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB). Cameron Myhrvold Ph.D., co-founder...

ASMB : 12.65 (-5.31%)
PRDS : 2.16 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Pardes Biosciences Inc. is a clinical-stage biopharmaceutical company. It discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines. The company's lead product candidate includes PBI-0451, is being developed as a direct-acting, oral antiviral drug...

See More

Key Turning Points

3rd Resistance Point 2.26
2nd Resistance Point 2.23
1st Resistance Point 2.19
Last Price 2.16
1st Support Level 2.13
2nd Support Level 2.10
3rd Support Level 2.06

See More

52-Week High 3.93
Fibonacci 61.8% 2.72
Fibonacci 50% 2.34
Last Price 2.16
Fibonacci 38.2% 1.96
52-Week Low 0.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar